These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30135544)

  • 1. Glycosylation Significantly Inhibits the Aggregation of Human Prion Protein and Decreases Its Cytotoxicity.
    Yi CW; Wang LQ; Huang JJ; Pan K; Chen J; Liang Y
    Sci Rep; 2018 Aug; 8(1):12603. PubMed ID: 30135544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoform-selective prion formation in sporadic and familial forms of prion disease.
    Xiao X; Yuan J; Haïk S; Cali I; Zhan Y; Moudjou M; Li B; Laplanche JL; Laude H; Langeveld J; Gambetti P; Kitamoto T; Kong Q; Brandel JP; Cobb BA; Petersen RB; Zou WQ
    PLoS One; 2013; 8(3):e58786. PubMed ID: 23527023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing Mutations Significantly Inhibit Amyloid Formation by Human Prion Protein and Decrease Its Cytotoxicity.
    Huang JJ; Li XN; Liu WL; Yuan HY; Gao Y; Wang K; Tang B; Pang DW; Chen J; Liang Y
    J Mol Biol; 2020 Feb; 432(4):828-844. PubMed ID: 31821812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoskeleton-dependent clustering of membrane-bound prion protein on the cell surface.
    Hackl S; Ng XW; Lu D; Wohland T; Becker CFW
    J Biol Chem; 2021; 296():100359. PubMed ID: 33539927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methionine oxidation within the prion protein.
    Bettinger J; Ghaemmaghami S
    Prion; 2020 Dec; 14(1):193-205. PubMed ID: 32744136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prion protein post-translational modifications modulate heparan sulfate binding and limit aggregate size in prion disease.
    Callender JA; Sevillano AM; Soldau K; Kurt TD; Schumann T; Pizzo DP; Altmeppen H; Glatzel M; Esko JD; Sigurdson CJ
    Neurobiol Dis; 2020 Aug; 142():104955. PubMed ID: 32454127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving views in prion glycosylation: functional and pathological implications.
    Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
    Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.
    Pan T; Wong P; Chang B; Li C; Li R; Kang SC; Wisniewski T; Sy MS
    J Virol; 2005 Jan; 79(2):934-43. PubMed ID: 15613322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial human prion diseases associated with prion protein mutations Y226X and G131V are transmissible to transgenic mice expressing human prion protein.
    Race B; Williams K; Hughson AG; Jansen C; Parchi P; Rozemuller AJM; Chesebro B
    Acta Neuropathol Commun; 2018 Feb; 6(1):13. PubMed ID: 29458424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation.
    Bamia A; Sinane M; Naït-Saïdi R; Dhiab J; Keruzoré M; Nguyen PH; Bertho A; Soubigou F; Halliez S; Blondel M; Trollet C; Simonelig M; Friocourt G; Béringue V; Bihel F; Voisset C
    Neurotherapeutics; 2021 Apr; 18(2):1137-1150. PubMed ID: 33533011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic disorder and phase transitions: Pieces in the puzzling role of the prion protein in health and disease.
    do Amaral MJ; Cordeiro Y
    Prog Mol Biol Transl Sci; 2021; 183():1-43. PubMed ID: 34656326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of cell-surface prion protein relative to its recombinant analogue: insights from molecular dynamics simulations of diglycosylated, membrane-bound human prion protein.
    DeMarco ML; Daggett V
    J Neurochem; 2009 Apr; 109(1):60-73. PubMed ID: 19226372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.
    Wolf H; Graßmann A; Bester R; Hossinger A; Möhl C; Paulsen L; Groschup MH; Schätzl H; Vorberg I
    J Virol; 2015 Oct; 89(19):9853-64. PubMed ID: 26202247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
    Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialylation of the prion protein glycans controls prion replication rate and glycoform ratio.
    Katorcha E; Makarava N; Savtchenko R; Baskakov IV
    Sci Rep; 2015 Nov; 5():16912. PubMed ID: 26576925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
    Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
    Prion; 2015; 9(5):394-403. PubMed ID: 26555211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of the glycosylation of prion protein provokes apoptosis in SF126.
    Chen L; Yang Y; Han J; Zhang BY; Zhao L; Nie K; Wang XF; Li F; Gao C; Dong XP; Xu CM
    J Biochem Mol Biol; 2007 Sep; 40(5):662-9. PubMed ID: 17927898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective retrotranslocation causes loss of anti-Bax function in human familial prion protein mutants.
    Jodoin J; Laroche-Pierre S; Goodyer CG; LeBlanc AC
    J Neurosci; 2007 May; 27(19):5081-91. PubMed ID: 17494694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.